EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 193 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR El cáncer en mi comunidad: Ampliar el acceso a las pruebas... September 1, 2020 Only a Quarter of Phase III Studies Demonstrated Improved QoL in... July 18, 2022 Advancing Patient Care Through Focused Innovation April 16, 2018 Increasing Education About Cancer Screening and Prevention in Kazakhstan May 11, 2021 Load more HOT NEWS Women in Science: Celebrating with our Women of Influence initiative Childhood cancer survivors at greater risk of ill health Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer EMA Recommends Extending Indications for Lisocabtagene Maraleucel
